16:54 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Ascentage continues trend of large Chinese-led rounds

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) raised about $150 million in a series C round co-led by existing investors YuanMing Prudence Fund and Oriza Seed Venture Capital and new investor Teng Yue Partners....
11:00 , Jul 17, 2018 |  BC Extra  |  Financial News

Ascentage continues trend of large Chinese-led rounds

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) raised about $150 million in a series C round co-led by existing investors YuanMing Prudence Fund and Oriza Seed Venture Capital and new investor Teng Yue Partners....
18:11 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Ascentage reports Phase I data for APG-1252 in solid tumors

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) reported interim data from 13 evaluable patients with solid tumors, including six with small cell lung cancer (SCLC), in a Phase I trial showing that APG-1252 led...
00:39 , Jan 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); multiple myeloma (MM) In vitro and cell culture studies suggest stapled peptide inhibitors of MCL1 could help treat ALL and MM. Modification of previously identified peptide-based inhibitors of MCL1 with hydrocarbon...
21:17 , Jan 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer; ovarian cancer Cell culture and mouse studies suggest inhibiting USP13 could help treat lung and ovarian cancers. In samples from lung cancer patients, USP13 levels were higher in tumor samples than in adjacent...
20:58 , Dec 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune

INDICATION: Scleroderma Cell culture and mouse studies suggest inhibiting Bcl-XL could help treat scleroderma. In primary human dermal fibroblasts cultured on a stiff matrix to mimic fibrotic conditions, siRNA targeting Bcl-XL or a Bcl-XL inhibitor tool...
05:31 , Dec 15, 2017 |  BC Extra  |  Preclinical News

A new role for Bcl-XL in fibrosis

In a paper published in Science Translational Medicine, researchers from Harvard Medical School and colleagues suggest that inhibiting the anti-apoptotic protein Bcl-XL could treat fibrosis and describe a cell-based assay to stratify scleroderma patients into...
22:58 , Nov 14, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer; prostate cancer Cell culture and mouse studies suggest Bcl-XL inhibitors could help treat glioma, prostate and other cancers harboring the IDH1 R123H mutation. In human glioma and prostate cancer cell lines, cells engineered...
20:46 , Oct 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Transplant Cell culture and mouse studies suggest transient overexpression of Bcl-XL in hematopoietic stem cells (HSCs) ex vivo could help improve outcomes of HSC transplants in cancer patients. In an assay of etoposide-induced apoptosis in...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...